Thomas Schmidt, 21st.BIO CEO (via 21st.BIO website)

No­vo Hold­ings to help young Dan­ish com­pa­ny with ef­forts to pro­vide scale to start-ups

A Dan­ish bio in­dus­tri­al scale-up com­pa­ny has land­ed an $86 mil­lion in­vest­ment from No­vo Hold­ings, and it’s hop­ing to build on a tech­nol­o­gy base from Novozymes. And with that in­vest­ment will come a new man­u­fac­tur­ing site.

21st.BIO was found­ed in 2020, and is fo­cused on sup­port­ing the up­scal­ing of com­pa­nies across the world, with the in­ten­tion of help­ing those com­pa­nies meet mar­ket de­mand. Its fo­cus are pep­tides and pro­teins, and it wants to pro­vide star­tups ac­cess to fa­cil­i­ties to de­vel­op a mol­e­cule pro­duc­tion process that can de­liv­er a high-qual­i­ty prod­uct in the most cost-ef­fec­tive way.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.